Acasti Pharma Inc
(NASDAQ:ACST)
$2.3102
0.0802[3.60%]
Last update: 3:31PM (Delayed 15-Minutes)
Get Real Time Here
$2.25
-0.0602[-2.61%]
After-Hours
Open2.245Close-
Vol / Avg.7.160K / 50.032KMkt Cap21.715M
Day Range2.160 - 2.38052 Wk Range1.720 - 20.660

Acasti Pharma Stock (NASDAQ:ACST), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$2.40

Consensus Price Target1

$3.63

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
30000

Analyst Firms Making Recommendations1

  • EF Hutton
  • HC Wainwright & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Acasti Pharma

Upgrades (0)

Downgrades (0)

Initiations (4)

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/15/2023ACSTBuy Now
Acasti Pharma
$2.318.22%EF Hutton
Constantine Davides
→ $15Reiterates → BuyGet Alert
12/19/2022ACSTBuy Now
Acasti Pharma
$2.318.22%EF Hutton
Constantine Davides
→ $15Initiates → BuyGet Alert
12/15/2022ACSTBuy Now
Acasti Pharma
$2.313.89%HC Wainwright & Co.
Oren Livnat
→ $14.4Initiates → BuyGet Alert
12/22/2021ACSTBuy Now
Acasti Pharma
$2.31159.72%Oppenheimer
Leland Gershell
→ $36Initiates → OutperformGet Alert
12/21/2021ACSTBuy Now
Acasti Pharma
$2.31159.72%Oppenheimer
Leland Gershell
→ $36Initiates → OutperformGet Alert
Q

What is the target price for Acasti Pharma (ACST)?

A

The latest price target for Acasti Pharma (NASDAQ: ACST) was reported by EF Hutton on February 15, 2023. The analyst firm set a price target for $2.50 expecting ACST to rise to within 12 months (a possible 8.22% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Acasti Pharma (ACST)?

A

The latest analyst rating for Acasti Pharma (NASDAQ: ACST) was provided by EF Hutton, and Acasti Pharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Acasti Pharma (ACST)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acasti Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acasti Pharma was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.

Q

Is the Analyst Rating Acasti Pharma (ACST) correct?

A

While ratings are subjective and will change, the latest Acasti Pharma (ACST) rating was a reiterated with a price target of $0.00 to $2.50. The current price Acasti Pharma (ACST) is trading at is $2.31, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.